Omalizumab: a review of its use in the management of allergic asthma

Treatments in Respiratory Medicine
Lynne M Bang, Greg L Plosker

Abstract

Omalizumab (Xolair) is a humanized monoclonal antibody used in the treatment of adolescent and adult patients with moderate to severe allergic asthma inadequately controlled with inhaled corticosteroids (ICS). It selectively binds to circulating immunoglobulin E (IgE) and, thereby, prevents binding of IgE to mast cells and other effector cells. Without surface-bound IgE, these cells are unable to recognize allergens, thus preventing cellular activation by antigens and the subsequent allergic/asthmatic symptoms. Omalizumab decreases free serum IgE levels in a dose-dependent manner, reduces IgE receptor density on effector cells, and significantly improves airway inflammation parameters. Omalizumab is slowly absorbed after subcutaneous administration, and mean elimination half-life is 26 days, thus allowing infrequent administration of the drug. Omalizumab dosage is determined by bodyweight and pretreatment serum total IgE levels. Patients treated with subcutaneous omalizumab in clinical trials received a dosage that was approximately equal to 0.016 mg/kg/IgE (IU/mL) per 4 weeks. Thus, patients received 150 or 300 mg every 4 weeks, or 225, 300, or 375 mg every 2 weeks. In adults and adolescents (> or =12 years of age) with modera...Continue Reading

References

May 1, 1995·International Archives of Allergy and Immunology·R L ShieldsP Jardieu
Apr 1, 1993·The American Review of Respiratory Disease·E F JuniperL E Griffith
Jun 1, 1997·American Journal of Respiratory and Critical Care Medicine·J V FahyH A Boushey
Jun 1, 1997·American Journal of Respiratory and Critical Care Medicine·L P BouletD W Cockcroft
Dec 23, 1999·The New England Journal of Medicine·H MilgromW J Metzger
May 22, 2003·International Archives of Allergy and Immunology·Oliver NogaGert Kunkel
Sep 4, 2003·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·Bobby Quentin LanierNiroo Gupta
Sep 4, 2003·Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology·William BergerAngel Fowler-Taylor
Jan 15, 2004·American Journal of Respiratory Medicine : Drugs, Devices, and Other Interventions·William Storms
Apr 15, 2004·Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology·S T HolgateUNKNOWN Omalizumab 011 International Study Group

❮ Previous
Next ❯

Citations

Apr 11, 2014·Human Vaccines & Immunotherapeutics·Salvatore Chirumbolo
Jan 12, 2019·Expert Opinion on Drug Metabolism & Toxicology·Diego BagnascoGiorgio Walter Canonica
Sep 29, 2005·Expert Opinion on Biological Therapy·David Ternant, Gilles Paintaud
Jan 10, 2013·Clinical Pharmacokinetics·Miroslav DostalekManoranjenni Chetty
Jul 28, 2016·PloS One·Fábio Vitarelli MarinhoCristina T Fonseca
May 17, 2008·BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy·Greg L Plosker, Susan J Keam
Apr 24, 2020·Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology·Ziyuan HeSandra Andorf
Apr 20, 2021·Brazilian Journal of Otorhinolaryngology·Wilma T Anselmo-LimaFabiana C P Valera

❮ Previous
Next ❯

Related Concepts

Related Feeds

Asthma

This feed focuses in Asthma in which your airways narrow and swell. This can make breathing difficult and trigger coughing, wheezing and shortness of breath.

Allergy and Asthma

Allergy and asthma are inflammatory disorders that are triggered by the activation of an allergen-specific regulatory t cell. These t cells become activated when allergens are recognized by allergen-presenting cells. Here is the latest research on allergy and asthma.

Related Papers

BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
Lynne M Bang, Greg L Plosker
BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy
Greg L Plosker, Susan J Keam
Drugs
S Easthope, B Jarvis
Current Pharmaceutical Design
L M DuBuske
© 2022 Meta ULC. All rights reserved